HUP0103431A3 - Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent - Google Patents

Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent

Info

Publication number
HUP0103431A3
HUP0103431A3 HU0103431A HUP0103431A HUP0103431A3 HU P0103431 A3 HUP0103431 A3 HU P0103431A3 HU 0103431 A HU0103431 A HU 0103431A HU P0103431 A HUP0103431 A HU P0103431A HU P0103431 A3 HUP0103431 A3 HU P0103431A3
Authority
HU
Hungary
Prior art keywords
agonists
antagonists
pharmaceutical
active agent
compositions containing
Prior art date
Application number
HU0103431A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0103431(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9818340.3A external-priority patent/GB9818340D0/en
Priority claimed from GBGB9823477.6A external-priority patent/GB9823477D0/en
Priority claimed from GBGB9910320.2A external-priority patent/GB9910320D0/en
Priority claimed from GBGB9911059.5A external-priority patent/GB9911059D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0103431A2 publication Critical patent/HUP0103431A2/hu
Publication of HUP0103431A3 publication Critical patent/HUP0103431A3/hu
Publication of HU228179B1 publication Critical patent/HU228179B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Indole Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Peptides Or Proteins (AREA)
HU0103431A 1998-08-21 1999-08-19 Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent HU228179B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9818340.3A GB9818340D0 (en) 1998-08-21 1998-08-21 Organic compounds
GBGB9823477.6A GB9823477D0 (en) 1998-10-27 1998-10-27 Organic compounds
GBGB9910320.2A GB9910320D0 (en) 1999-05-05 1999-05-05 Organic compounds
GBGB9911059.5A GB9911059D0 (en) 1999-05-12 1999-05-12 Organic compounds
PCT/EP1999/006083 WO2000010526A2 (en) 1998-08-21 1999-08-19 New oral formulation for 5-ht4 agonists or antagonists

Publications (3)

Publication Number Publication Date
HUP0103431A2 HUP0103431A2 (hu) 2002-01-28
HUP0103431A3 true HUP0103431A3 (en) 2002-02-28
HU228179B1 HU228179B1 (en) 2013-01-28

Family

ID=27451823

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103431A HU228179B1 (en) 1998-08-21 1999-08-19 Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent

Country Status (29)

Country Link
US (4) US20030236183A1 (hu)
EP (1) EP1104289B1 (hu)
JP (1) JP4048024B2 (hu)
KR (1) KR100529659B1 (hu)
CN (2) CN1589906A (hu)
AT (1) ATE316782T1 (hu)
AU (4) AU762829B2 (hu)
BG (1) BG65322B1 (hu)
BR (1) BR9913135A (hu)
CA (1) CA2338794C (hu)
CZ (1) CZ300647B6 (hu)
DE (1) DE69929703T2 (hu)
DK (1) DK1104289T3 (hu)
EE (1) EE05054B1 (hu)
ES (1) ES2257869T3 (hu)
FR (3) FR2782454B1 (hu)
HR (1) HRP20010123B1 (hu)
HU (1) HU228179B1 (hu)
ID (1) ID28510A (hu)
IL (1) IL141236A0 (hu)
IS (1) IS2369B (hu)
IT (1) IT1314185B1 (hu)
NO (1) NO328756B1 (hu)
NZ (1) NZ509832A (hu)
PL (2) PL194069B1 (hu)
RS (1) RS50104B (hu)
SK (1) SK285255B6 (hu)
TR (3) TR200102259T2 (hu)
WO (1) WO2000010526A2 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001270304A1 (en) 2000-07-07 2002-01-21 The Administrators Of The Tulane Educational Fund Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
CA2428386A1 (en) * 2000-11-24 2002-05-30 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
US20050119328A1 (en) * 2003-03-25 2005-06-02 Hetero Drugs Limited Novel crysalline forms of tegaserod maleate
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
PE20050253A1 (es) * 2003-07-24 2005-06-03 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US8591974B2 (en) 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP3449928A1 (en) 2005-11-28 2019-03-06 Imaginot Pty Ltd. Oral therapeutic compound delivery system
EP2493457B1 (en) 2009-10-30 2017-08-09 IX Biopharma Ltd Fast dissolving solid dosage form
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
WO2013026565A1 (de) 2011-08-20 2013-02-28 Advanced Medical Balloons Trans-analer einlaufkatheter und verfahren zur intermittierenden auslösung einer reflexkoordinierten defäkation
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552398A (en) * 1895-12-31 Riveting-machine
JP2708803B2 (ja) * 1987-09-02 1998-02-04 中外製薬株式会社 持続放出製剤
IE912955A1 (en) * 1990-08-24 1992-02-26 Spirig Ag Process for the production of pellets
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
US20020128172A1 (en) * 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
FR2710915B1 (fr) * 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
TW270114B (hu) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
WO1996016639A1 (en) * 1994-12-01 1996-06-06 Cibus Pharmaceutical, Inc. Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
FR2753196B1 (fr) * 1996-09-12 1998-10-23 Synthelabo Derives d'indazole tricyclique, leur preparation et leur application en therapeutique
AU1931999A (en) * 1997-12-19 1999-07-12 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod

Also Published As

Publication number Publication date
ITMI991826A0 (it) 1999-08-19
FR2784899A1 (fr) 2000-04-28
EE200100104A (et) 2002-06-17
WO2000010526A3 (en) 2000-09-08
NO20010863L (no) 2001-03-26
US20130158092A1 (en) 2013-06-20
FR2799123A1 (fr) 2001-04-06
PL200132B1 (pl) 2008-12-31
HU228179B1 (en) 2013-01-28
IT1314185B1 (it) 2002-12-06
EP1104289B1 (en) 2006-02-01
JP2002523351A (ja) 2002-07-30
ID28510A (id) 2001-05-31
FR2799123B1 (fr) 2005-12-02
US20120071537A1 (en) 2012-03-22
FR2782454B1 (fr) 2005-12-02
IS2369B (is) 2008-06-15
PL194069B1 (pl) 2007-04-30
CA2338794A1 (en) 2000-03-02
HRP20010123A2 (en) 2002-02-28
AU2006200048A1 (en) 2006-02-02
AU5623299A (en) 2000-03-14
BG105257A (en) 2001-11-30
EE05054B1 (et) 2008-08-15
RS50104B (sr) 2009-01-22
AU2003248212A1 (en) 2003-10-30
AU2009200403A1 (en) 2009-02-26
NO328756B1 (no) 2010-05-03
TR200100361T2 (tr) 2001-06-21
NO20010863D0 (no) 2001-02-20
SK285255B6 (sk) 2006-09-07
CZ300647B6 (cs) 2009-07-08
WO2000010526A2 (en) 2000-03-02
HRP20010123B1 (hr) 2010-11-30
KR100529659B1 (ko) 2005-11-21
US20030236183A1 (en) 2003-12-25
NZ509832A (en) 2003-11-28
PL346764A1 (en) 2002-02-25
DE69929703T2 (de) 2007-02-22
US20080075773A1 (en) 2008-03-27
FR2784899B1 (fr) 2001-08-17
BG65322B1 (bg) 2008-02-29
DK1104289T3 (da) 2006-05-15
KR20010079668A (ko) 2001-08-22
ITMI991826A1 (it) 2001-02-19
CA2338794C (en) 2009-01-20
AU762829B2 (en) 2003-07-03
EP1104289A2 (en) 2001-06-06
ES2257869T3 (es) 2006-08-01
ATE316782T1 (de) 2006-02-15
CZ2001619A3 (en) 2001-05-16
IS5851A (is) 2001-01-20
TR200102259T2 (tr) 2002-06-21
YU8701A (sh) 2003-12-31
SK2432001A3 (en) 2001-09-11
FR2782454A1 (fr) 2000-02-25
JP4048024B2 (ja) 2008-02-13
HUP0103431A2 (hu) 2002-01-28
CN1165293C (zh) 2004-09-08
DE69929703D1 (de) 2006-04-13
CN1589906A (zh) 2005-03-09
IL141236A0 (en) 2002-03-10
BR9913135A (pt) 2001-05-08
HK1038179A1 (en) 2002-03-08
TR200400187T2 (tr) 2006-11-21
CN1323200A (zh) 2001-11-21

Similar Documents

Publication Publication Date Title
HUP0103431A3 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
HUP0103567A3 (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists, process for their preparation and pharmaceutical compositions containing the same
HUP0302969A3 (en) Npyy5 antagonists, pharmaceutical compositions containing them and their use
IL154981A0 (en) Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
EE04450B1 (et) Farmatseutilised kompositsioonid kahe või enama toimeainega aerosoolidele
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
HUP0203973A3 (en) Heterocyclic compounds having sulfonamide groups, pharmaceutical compositions containing them and their use
HUP0303432A3 (en) Substituted pyridoindoles as serotonin agonists and antagonists and pharmaceutical compositions containing the compounds and their use
HUP0102676A3 (en) Solid, quick dissolving pharmaceutical compositions containing cetrizine
HUP0201545A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them
HUP0200355A3 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0103341A3 (en) Azetidine derivatives, preparation and pharmaceutical compositions thereof
HUP0203638A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them and their use
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
DZ3313A1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
HUP0203403A3 (en) New imidazole derivatives, pharmaceutical compositions containing them and their use
IL150346A (en) Benzazole derivatives, their preparation and pharmaceutical compositions containing them
HUP0102453A3 (en) Adenosine derivatives, their use and pharmaceutical compositions containing the compounds
IL148876A0 (en) Sulfonamide derivatives, their preparation and pharmaceutical compositions containing them
HUP0103884A3 (en) Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use
HUP0203836A3 (en) 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
HUP0204081A3 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
HUP0102334A3 (en) Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing the compound
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients